Challenges to generic medicines utilization in Yemeni healthcare system
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 2
Abstract
Generic medicines are promoted in many countries as an essential part of the healthcare system. However, in Yemen, there are many challenges to the utilisation of generic medicines. Currently, there is no national level policy to enhance or promote generic medicines use. In addition, other challenges to the use of generic medicines in Yemen including negative perceptions and availability of counterfeit medicines are highlighted in this brief report.
Authors and Affiliations
Saleh Karamah AL-Tamimi, Mohamed Azmi Ahmad Hassali, Alian A Alrasheedy
Keywords
Related Articles
- EP ID EP354980
- DOI 10.5639/gabij.2013.0202.017
- Views 142
- Downloads 0
The MEDICRIME Convention: criminalising the falsification of medicines and similar crimes
Trade in falsified/counterfeit medical products is a growing global criminal industry, posing a major threat to patients and healthcare systems. Falsified/Counterfeit medical products circulate via unregulated channels,...
Biosimilar monoclonal antibodies—challenges and opportunities in Europe
New regulations for the development of biosimilars have been introduced in Europe and a new class of biosimilars – monoclonal antibodies – is expected on the market soon, which will both challenge and benefit our healthc...
New EU guidance for the evaluation of medicinal products with modified drug release will be finished by the middle of 2014
The guideline ‘Note for guidance on modified release oral and transdermal dosage forms: Section II (Pharmacokinetic and clinical evaluation)’ [1] was issued over 10 years ago, and the need for revision was recognized in...
Equal protection under the law: Children and the Best Pharmaceuticals for Children Act
Four changes to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act will markedly improve these programmes: expanded attention paid to neonatal studies, support for the off -patent programme,...
Biosimilars naming and prescribing policy in Australia
To the Editor: I wanted to bring to your attention the following paper which was published in Volume 2/Year 2013/Issue 3 of the Generics and Biosimilars Initiative Journal. The Perspective paper titled Licensing and pr...